Modality
Multispecific
MOA
SGLT2i
Target
Aβ
Pathway
T-cell
PsA
Development Pipeline
Preclinical
~Apr 2023
→ ~Jul 2024
Phase 1
Oct 2024
→ Nov 2031
Phase 1Current
NCT05311949
1,750 pts·PsA
2024-10→2031-11·Completed
NCT07338475
667 pts·PsA
2025-07→2031-05·Not yet recruiting
2,417 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-05-045.1y awayPh2 Data· PsA
2031-11-225.6y awayPh2 Data· PsA
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
P1/2
Not yet…
Catalysts
Ph2 Data
2031-05-04 · 5.1y away
PsA
Ph2 Data
2031-11-22 · 5.6y away
PsA
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05311949 | Phase 1/2 | PsA | Completed | 1750 | CR |
| NCT07338475 | Phase 1/2 | PsA | Not yet recr... | 667 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |